» Articles » PMID: 30264887

Long-term Relationships Between Screening Rates, Breast Cancer Characteristics, and Overdiagnosis in US Counties, 1975-2009

Overview
Journal Int J Cancer
Specialty Oncology
Date 2018 Sep 29
PMID 30264887
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Effects of mammography screening in the general population are disputed. Screening rates differ greatly between US counties, providing a natural opportunity to investigate effects of screening. We compared mammography screening rates with the types and outcomes of breast cancers diagnosed in US counties. The county screening rate was defined as the proportion of women age ≥40 with ≥1 mammogram in the past 2 years (range, 34-91%). Two periods were analyzed: 1975-2009 (612,941 breast cancer cases, 195 counties) and 1996-2009 (645,057 cases, 211-547 counties). Multiple signs of overdiagnosis were observed: First, breast cancer incidence increased as screening became common. Second, incidence stopped increasing once screening rates stabilized. Third, the increases in incidence were limited to age groups receiving screening. Fourth, the increases were larger in counties where screening became more common. Fifth, the increases were limited to small and early-stage breast cancers (which are consistent with overdiagnosis). Sixth, compensatory reductions in large and advanced-stage breast cancers were much smaller than the increases. Difference-in-differences regression analysis suggested 31% (95% CI: 28-34%) of breast cancers diagnosed in 1996-2009 were overdiagnosed. Screening rates correlated with increased incidence for all hormone receptor statuses, HER2 statuses, and grades. Reductions in breast cancer mortality during 1975-2009 were similar in screened and unscreened age groups. Overall, we found repeated signs that breast cancer overdiagnosis is widespread in the US, but the biological nature of overdiagnosed tumors remains unclear. Mortality benefits of screening, though they may be present and substantial, could not be detected at the population level.

Citing Articles

Supplemental Screening as an Adjunct to Mammography for Breast Cancer Screening in People With Dense Breasts: A Health Technology Assessment.

Ont Health Technol Assess Ser. 2024; 23(9):1-293.

PMID: 39364436 PMC: 11445669.


[Exploring the therapeutic mechanism of decoction for perimenopausal insomnia based on network pharmacology and animal experiments].

Zhang Q, Zhang M, Liu Y, Lv F, Wang Y Nan Fang Yi Ke Da Xue Xue Bao. 2023; 43(9):1536-1547.

PMID: 37814868 PMC: 10563099. DOI: 10.12122/j.issn.1673-4254.2023.09.11.


Prognostic value of XIAP and survivin expression in locally advanced breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy.

Pluta P, Jesionek-Kupnicka D, Pluta A, Brzozowski K, Braun M, Kubicka-Wolkowska J Arch Med Sci. 2023; 19(2):343-354.

PMID: 37034529 PMC: 10074301. DOI: 10.5114/aoms.2019.88509.


Overdiagnosis Due to Screening Mammography for Breast Cancer among Women Aged 40 Years and Over: A Systematic Review and Meta-Analysis.

Flemban A J Pers Med. 2023; 13(3).

PMID: 36983705 PMC: 10051653. DOI: 10.3390/jpm13030523.


A population health assessment of screening mammography on breast cancer mortality in North Carolina.

Burch A, Irish W, Wong J Breast Cancer Res Treat. 2022; 196(3):647-656.

PMID: 36287307 DOI: 10.1007/s10549-022-06773-3.